Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease

F. Locatelli, D. Marcelli, F. Conte, M. D'Amico, L. Del Vecchio, A. Limido, F. Malberti, D. Spotti

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). The aim of this study was to evaluate the influence of hemodialysis (HD) versus peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Of the 4191 patients with end-stage renal disease (ESRD) who started renal replacement treatment (RRT) in Lombardy between 1994 and 1997, 4064 (who were on dialysis 30 d after the start of RRT) were considered for survival analysis: 2772 were on HD (mean age 60.9 yr; 21.2% diabetic) and 1292 on PD (mean age 63.6 yr; 16% diabetic). The 3120 patients who were free of CVD at the start of RRT were included in the analysis of the risk of developing de novo CVD. HD and PD were compared by use of a Cox-regression proportional hazard model, stratified by diabetic status; the explanatory covariates were age and gender. The death rate was 13.3 per 100 patient-years (13.0 on HD and 13.9 on PD); 197 (6.3%) of the 3120 patients included in the CVD analysis developed de novo CVD (128 on HD and 69 on PD). After adjustment for age, gender, and established CVD and stratification by diabetic status, there was no significant betweentreatment difference in 4-yr survival (relative risk [RR], 0.91; 95% confidence interval ICI], 0.79 to 1.06). The risk of de novo CVD did not differ significantly by treatment modality (RR, 1.06; 95% CI, 0.79 to 1.43). The risk of mortality and de novo CVD for new patients with ESRD assigned to HD or PD was similar in Lombardy in the period 1994 through 1997.

Original languageEnglish
Pages (from-to)2411-2417
Number of pages7
JournalJournal of the American Society of Nephrology
Volume12
Issue number11
Publication statusPublished - 2001

Fingerprint

Chronic Kidney Failure
Cardiovascular Diseases
Peritoneal Dialysis
Survival
Renal Dialysis
Therapeutics
Kidney
Dialysis
Mortality
Survival Analysis
Proportional Hazards Models
Confidence Intervals

ASJC Scopus subject areas

  • Nephrology

Cite this

Locatelli, F., Marcelli, D., Conte, F., D'Amico, M., Del Vecchio, L., Limido, A., ... Spotti, D. (2001). Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. Journal of the American Society of Nephrology, 12(11), 2411-2417.

Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. / Locatelli, F.; Marcelli, D.; Conte, F.; D'Amico, M.; Del Vecchio, L.; Limido, A.; Malberti, F.; Spotti, D.

In: Journal of the American Society of Nephrology, Vol. 12, No. 11, 2001, p. 2411-2417.

Research output: Contribution to journalArticle

Locatelli, F, Marcelli, D, Conte, F, D'Amico, M, Del Vecchio, L, Limido, A, Malberti, F & Spotti, D 2001, 'Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease', Journal of the American Society of Nephrology, vol. 12, no. 11, pp. 2411-2417.
Locatelli, F. ; Marcelli, D. ; Conte, F. ; D'Amico, M. ; Del Vecchio, L. ; Limido, A. ; Malberti, F. ; Spotti, D. / Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. In: Journal of the American Society of Nephrology. 2001 ; Vol. 12, No. 11. pp. 2411-2417.
@article{6fdc4d89fe794ff792d4c08aa6047a54,
title = "Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease",
abstract = "Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). The aim of this study was to evaluate the influence of hemodialysis (HD) versus peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Of the 4191 patients with end-stage renal disease (ESRD) who started renal replacement treatment (RRT) in Lombardy between 1994 and 1997, 4064 (who were on dialysis 30 d after the start of RRT) were considered for survival analysis: 2772 were on HD (mean age 60.9 yr; 21.2{\%} diabetic) and 1292 on PD (mean age 63.6 yr; 16{\%} diabetic). The 3120 patients who were free of CVD at the start of RRT were included in the analysis of the risk of developing de novo CVD. HD and PD were compared by use of a Cox-regression proportional hazard model, stratified by diabetic status; the explanatory covariates were age and gender. The death rate was 13.3 per 100 patient-years (13.0 on HD and 13.9 on PD); 197 (6.3{\%}) of the 3120 patients included in the CVD analysis developed de novo CVD (128 on HD and 69 on PD). After adjustment for age, gender, and established CVD and stratification by diabetic status, there was no significant betweentreatment difference in 4-yr survival (relative risk [RR], 0.91; 95{\%} confidence interval ICI], 0.79 to 1.06). The risk of de novo CVD did not differ significantly by treatment modality (RR, 1.06; 95{\%} CI, 0.79 to 1.43). The risk of mortality and de novo CVD for new patients with ESRD assigned to HD or PD was similar in Lombardy in the period 1994 through 1997.",
author = "F. Locatelli and D. Marcelli and F. Conte and M. D'Amico and {Del Vecchio}, L. and A. Limido and F. Malberti and D. Spotti",
year = "2001",
language = "English",
volume = "12",
pages = "2411--2417",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "11",

}

TY - JOUR

T1 - Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease

AU - Locatelli, F.

AU - Marcelli, D.

AU - Conte, F.

AU - D'Amico, M.

AU - Del Vecchio, L.

AU - Limido, A.

AU - Malberti, F.

AU - Spotti, D.

PY - 2001

Y1 - 2001

N2 - Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). The aim of this study was to evaluate the influence of hemodialysis (HD) versus peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Of the 4191 patients with end-stage renal disease (ESRD) who started renal replacement treatment (RRT) in Lombardy between 1994 and 1997, 4064 (who were on dialysis 30 d after the start of RRT) were considered for survival analysis: 2772 were on HD (mean age 60.9 yr; 21.2% diabetic) and 1292 on PD (mean age 63.6 yr; 16% diabetic). The 3120 patients who were free of CVD at the start of RRT were included in the analysis of the risk of developing de novo CVD. HD and PD were compared by use of a Cox-regression proportional hazard model, stratified by diabetic status; the explanatory covariates were age and gender. The death rate was 13.3 per 100 patient-years (13.0 on HD and 13.9 on PD); 197 (6.3%) of the 3120 patients included in the CVD analysis developed de novo CVD (128 on HD and 69 on PD). After adjustment for age, gender, and established CVD and stratification by diabetic status, there was no significant betweentreatment difference in 4-yr survival (relative risk [RR], 0.91; 95% confidence interval ICI], 0.79 to 1.06). The risk of de novo CVD did not differ significantly by treatment modality (RR, 1.06; 95% CI, 0.79 to 1.43). The risk of mortality and de novo CVD for new patients with ESRD assigned to HD or PD was similar in Lombardy in the period 1994 through 1997.

AB - Patients undergoing dialysis are at high risk for cardiovascular disease (CVD). The aim of this study was to evaluate the influence of hemodialysis (HD) versus peritoneal dialysis (PD) on survival and the risk of developing de novo CVD. Of the 4191 patients with end-stage renal disease (ESRD) who started renal replacement treatment (RRT) in Lombardy between 1994 and 1997, 4064 (who were on dialysis 30 d after the start of RRT) were considered for survival analysis: 2772 were on HD (mean age 60.9 yr; 21.2% diabetic) and 1292 on PD (mean age 63.6 yr; 16% diabetic). The 3120 patients who were free of CVD at the start of RRT were included in the analysis of the risk of developing de novo CVD. HD and PD were compared by use of a Cox-regression proportional hazard model, stratified by diabetic status; the explanatory covariates were age and gender. The death rate was 13.3 per 100 patient-years (13.0 on HD and 13.9 on PD); 197 (6.3%) of the 3120 patients included in the CVD analysis developed de novo CVD (128 on HD and 69 on PD). After adjustment for age, gender, and established CVD and stratification by diabetic status, there was no significant betweentreatment difference in 4-yr survival (relative risk [RR], 0.91; 95% confidence interval ICI], 0.79 to 1.06). The risk of de novo CVD did not differ significantly by treatment modality (RR, 1.06; 95% CI, 0.79 to 1.43). The risk of mortality and de novo CVD for new patients with ESRD assigned to HD or PD was similar in Lombardy in the period 1994 through 1997.

UR - http://www.scopus.com/inward/record.url?scp=0034752398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034752398&partnerID=8YFLogxK

M3 - Article

C2 - 11675417

AN - SCOPUS:0034752398

VL - 12

SP - 2411

EP - 2417

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 11

ER -